The demand for dermatological drugs in Bosnia and Herzegovina has been steadily increasing over the years.
Customer preferences: Bosnians have become increasingly conscious of their skin health and are more willing to invest in dermatological drugs. This is due to the growing awareness of the importance of skincare, as well as the availability of a wider range of products. Customers are now more likely to seek out products that address specific skin concerns, such as acne or eczema, rather than using generic skincare products.
Trends in the market: The dermatological drugs market in Bosnia and Herzegovina is experiencing a shift towards more natural and organic products. Consumers are becoming more aware of the potential side effects of synthetic ingredients and are looking for safer alternatives. As a result, there has been an increase in demand for products that are free from harmful chemicals and are made from natural ingredients. There is also a growing trend towards multi-functional products that offer multiple benefits, such as moisturizing and sun protection.
Local special circumstances: Bosnia and Herzegovina has a relatively small market for dermatological drugs, which limits the number of products available. This has led to a situation where a few key players dominate the market, making it difficult for new entrants to gain a foothold. Additionally, the country's healthcare system is still developing, and access to specialist dermatologists can be limited in some areas. This means that patients may rely more heavily on over-the-counter products for treatment.
Underlying macroeconomic factors: Bosnia and Herzegovina has a developing economy, which has led to a growing middle class with increased purchasing power. This has contributed to the increased demand for dermatological drugs, as consumers are more willing to spend money on high-quality products. Additionally, the country's healthcare system is undergoing reforms to improve access to healthcare services, which may lead to increased demand for dermatological drugs in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
